Building on the results described for this limited number of patients, future studies are warranted in a larger cohort of EGFR patients and may require cross-border/international collaborations to further increase the statistical power for this oncogene-driven subset of NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.